WuXi AppTec - 2026Q1 - titanstockanalysis.com

WuXi AppTec’s financial results for the first quarter of 2026 show strong performance. Below is the summary:

Significant Revenue Growth: Total revenue for the first quarter was 12.44B RMB, a year-over-year increase of 28.8%. Excluding disposed businesses, revenue from continuing operations grew by 39.4% year-over-year.
Strong Core Chemistry Business: The WuXi Chemistry business saw revenue growth of 43.7% year-over-year, with revenue from small molecule D&M (development and manufacturing) services surging by 80.1%.
Significant Improvement in Profitability: Adjusted non-IFRS net profit reached 4.6B RMB, up 71.7% year-over-year. The adjusted non-IFRS gross margin rose to 50.4%, an increase of more than 8 percentage points compared to the same period last year.
Business Model Efficiency: Benefiting from an increased proportion of late-stage clinical and commercial projects, the company saw improved scale effects and capacity utilization, effectively driving profitability.
Robust Backlog: As of the end of March, the backlog for continuing operations stood at 59.77B RMB, a year-over-year increase of 23.6%, providing high visibility for future operations.

Full-Year Guidance Maintained: The company remains confident in achieving its full-year 2026 performance guidance.
Strategy Execution: Continues to execute the “Follow the Molecule” and “Win the Molecule” strategies. The pipeline for small molecule D&M projects continues to expand, reaching 3,550 molecules by the end of the first quarter, including 183 commercial and phase III clinical projects, with 9 new related projects added in the first quarter.
Capacity Planning: To meet market demand, the company is accelerating its capacity expansion plans, including the early initiation of construction on the new Changzhou facility.
Emerging Businesses: The TIDES (oligonucleotides and peptides) business continues to grow rapidly, with revenue expected to increase by approximately 40% for the full year.

Based on aggregated forecasts from market institutions as of late May 2026:

2026 Annual EPS Forecast: Approximately 5.97 RMB.
Analysis: Following the strong Q1 earnings report, several major investment banks (such as Morgan Stanley and Goldman Sachs) raised their target prices, giving positive assessments of the sustainability of the company’s revenue and profit growth.

Sources: